))
The Silent Killer: Why biotechs are all in on kidney disease, with University of Sydney CTC and Chris Kallos
Manage episode 435363653 series 3594399
Contenuto fornito da Soundcraft Media. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Soundcraft Media o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Kidney disease is a silent killer, with only 10% of all people knowing they have it before damage has been done.
But in the last five years there's been a surge of work that's resulted in the FDA approving some blockbuster drugs in the last 18 months. Billion-dollar takeovers are now on the table and the tiny number of Australian biotechs in this sector have a front row seat to the action.
This series explains the mighty leaps that have already come, interviews the key biotech leaders in Australia working to treat and to cure kidney diseases, and joins the dots between what is happening today… and what could happen in the blue skies of the next 20 to 50 years.
Episode 1 features Professor Meg Jardine, director of the NHMRC Clinical Trials Centre, a flagship research organisation at the University of Sydney, where she is head of the Kidney Health research program, and investment analyst Chris Kallos. They explain why kidney disease is so hot right now from a science perspective and for investors.
Produced by Rachel Williamson and Charis Palmer. Music and effect credits to Ziso, Inspector J, Seth Parson and Boom Library.
Capitoli
1. The Silent Killer: Why biotechs are all in on kidney disease, with University of Sydney CTC and Chris Kallos (00:00:00)
2. Professor Meg Jardine (00:02:22)
3. Investment analyst Chris Kallos (00:15:55)
11 episodi
Condividi
